1. Home
  2. NXG vs DCTH Comparison

NXG vs DCTH Comparison

Compare NXG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NXG NextGen Infrastructure Income Fund of Beneficial Interest

NXG

NXG NextGen Infrastructure Income Fund of Beneficial Interest

HOLD

Current Price

$53.78

Market Cap

301.9M

Sector

N/A

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.01

Market Cap

311.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXG
DCTH
Founded
2012
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.9M
311.7M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
NXG
DCTH
Price
$53.78
$11.01
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
44.5K
272.1K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
14.78%
N/A
EPS Growth
N/A
107.53
EPS
N/A
0.07
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
N/A
$155.43
Revenue Growth
N/A
N/A
52 Week Low
$39.30
$8.12
52 Week High
$57.05
$18.23

Technical Indicators

Market Signals
Indicator
NXG
DCTH
Relative Strength Index (RSI) 48.02 74.08
Support Level $50.81 $10.50
Resistance Level $55.26 $11.25
Average True Range (ATR) 1.48 0.32
MACD -0.18 0.18
Stochastic Oscillator 37.64 95.63

Price Performance

Historical Comparison
NXG
DCTH

About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest

Cushing NextGen Infrastructure Income Fund is a closed-end management investment company. Its investment objective is to seek a high total return with an emphasis on current income. The fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies and technology and communication infrastructure companies.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: